With the goal of altering gene expression patterns in K562, construct a compound that increases the expression of SAMD4B, MEIOB, FANCG, TXNIP, SMG6, BCL7B, LUC7L, SREK1, CEP68, SHQ1, SPIDR, ALKBH2, HMGXB4, TPM3, MCUB, MBTPS1, NIP7, EIF4A2, PRCP, DRAP1, APOC1, WASHC1, TLE3, VKORC1, KBTBD6 and decreases the expression of ATPSCKMT, MFHAS1, ZNF260, DCAF16, RALGAPB, JPT1, IDH2, USB1, POGLUT2, SLF1, PLCG2, FYN, SRRM2, E4F1, TIMM10, ZNF12, UQCRC1, CPNE1, RAPGEF1, DPP3, KIF16B, DIAPH1, COX19, KIF20B, SENP5.
In a cell population characterized as K562, formulate a compound that will upregulate the expression of PRG2, CEP85L, PET100, PSD4, FBXL8, UCP2, GNL3, AF117829.1, RAB5C, TCF3, C5orf24, RNF31, SLC20A1, NUDT9, NCAPH2, XKR3, CAPG, RUNX1, CD53, IKZF4, BICD1, PEX16, DFFA, GINM1, SERTAD1, CDKN1C, KIAA0355 and downregulate the expression of USP32, KLHDC10, OGT, TSG101, NRIP3, HIST1H3H, KNSTRN, HOXB2, RHOT1, OTUD4, MRPL10, ZNF689, POLG2, ATG5, MTCH1, SMS, CAPRIN1, RBM27, IER3IP1, NUBP1, CPNE3, PTCD1, MYD88.